UTI Summary Notes

Urinary Tract Infections (UTI) Overview

  • Most common infectious diseases globally, characterized by significant bacteriuria.

  • Classified into upper (e.g., pyelonephritis) and lower (e.g., urethritis, cystitis) UTIs.

  • Predominantly caused by Enterobacteriaceae, especially Escherichia coli (80\%).

  • Symptoms: suprapubic pain, dysuria, urinary urgency, and frequency.

  • Diagnosis: urinalysis (pyuria, positive leukocyte esterase\/nitrites) and urine culture.

  • Empiric treatment for uncomplicated cystitis: trimethoprim-sulfamethoxazole, nitrofurantoin, fosfomycin.

  • 40\% of sepsis cases linked to UTIs.

UTI Pathogens

  • Common Bacteria:

    • E. coli (main causative agent)

    • Proteus mirabilis (produces urease, causes alkaline urine)

    • Klebsiella pneumoniae, Enterobacter species.

    • Other bacteria include Staphylococcus saprophyticus and Enterococci.

  • Viral Causes: Adenoviruses (hemorrhagic cystitis).

  • Yeast: Rarely due to Candida species.

Uropathogenic E. coli (UPEC)

  • Most frequent UTI cause with varying severity (asymptomatic to pyelonephritis).

  • Virulence factors boost infectivity: pili, surface antigens (O, K), siderophores, toxins.

  • Attachment via type 1 pili necessary for infection establishment.

  • Can persist intracellularly, evading immune responses.

Other Pathogens

  • Proteus mirabilis:

    • Known for forming crystalline biofilms.

    • Urease production contributes to urolithiasis.

  • Klebsiella spp.:

    • Opportunistic pathogens, often hospital-acquired.

    • Notable for antibiotic resistance mechanisms (ESBLs, carbapenemases).

Management of UTIs

  • First-line treatment: Nitrofurantoin or trimethoprim (low-resistance risk).

  • Second-line treatment: If no improvement, consider fosfomycin or pivmecillinam.

  • D-mannose Treatment:

    • A simple sugar often used for the prevention and management of recurrent UTIs, particularly those caused by E. coli.

    • Affected Stage: It primarily targets the initial stage of infection, which is the bacterial adhesion or colonization phase.

    • Mechanism: It functions via competitive inhibition by binding to the FimH adhesin on the type 1 pili of UPEC, preventing the bacteria from adhering to the mannosylated receptors on the bladder wall (urothelium).

    • It is often considered a non-antibiotic alternative or supplement, potentially reducing the need for repeated antibiotic cycles.

  • Innovative therapies: Bacteriophage therapy as a potential adjunct to antibiotics.

  • Self-care recommendations: Includes proper hydration and the use of cranberry products (containing proanthocyanidins), though clinical evidence for the latter remains variable.

Key Takeaways

  • UTIs are primarily endogenous infections